Buy & Sell Dollar General Corp. (DG) – Dollar General Corp. Price Today
Aura AI Summary
Key Stats
- $24.36BMarket Cap
- Consumer StaplesSector
- -33.51%3M Drawdown
- $38.94BEnterprise Value
- 2.13%Dividend Yield
- 58 daysTypical Hold Time
Dollar General Corp. (DG) is currently valued at a market capitalization of $24.36B, with an enterprise value of $38.94B. Over the past 52 weeks, Dollar General Corp. has traded between a low of $95.94 and a high of $156.26, highlighting its annual price range. Over the past three months, Dollar General Corp. has recorded a drawdown of -33.51%, reflecting recent price volatility. Dollar General Corp. offers a dividend yield of 2.13%, with the most recent dividend of $0.59 paid on 07 Apr 26. On average, investors hold Dollar General Corp. for approximately 58 days, indicating typical investor behavior on the platform.
About Dollar General Corp.
A leading American discount retailer, Dollar General operates over 18,000 stores in 47 states, selling branded and private-label products across a wide variety of categories. In fiscal 2021, 77% of net sales came from consumables (including paper and cleaning products, packaged and perishable food, tobacco, and health and beauty items), 12% from seasonal merchandise (such as toys, greeting cards, decorations, and gardening supplies), 7% from home products (for example, kitchen supplies, small appliances, and cookware), and 4% from basic apparel. Stores average roughly 7,400 square feet, and about 75% of Dollar General locations are in towns of 20,000 or fewer people. The firm emphasizes value, with most of its items sold at everyday low prices of $5 or less.
Most Recent News
Whitehawk reveals SEZ6 as a promising target for new cancer drug HWK-206, advancing to clinical trials in 2026.
Whitehawk Therapeutics announced data showing SEZ6 protein is highly expressed in small cell lung cancer (SCLC) and other neuroendocrine tumors, exceeding other known targets. This supports their development of HWK-206, a next-generation antibody dru...
PAPZIMEOS shows 83% durable response in RRP patients with FDA granting 7-year market exclusivity
Precigen's PAPZIMEOS, the first FDA-approved therapy for recurrent respiratory papillomatosis (RRP), demonstrated durable complete responses in 83% of patients over at least 36 months without additional treatment. Five patients maintained responses b...
AI crypto sector nears $26.6B as Ruvi AI launches major upgrade and unique token burn model.
The AI cryptocurrency sector reached a market cap of about $26.6 billion in May 2026, led by projects like Chainlink and NEAR Protocol. Ruvi AI (RUVI) stands out by integrating over 20 AI models into a decentralized platform that rewards contributors...